AMENDMENT

In the Claims

Please amend the claims as follows:

103. (Amended three times) A process of isolating a substance with an ability to act as a specific agonist of a kappa opioid receptor, said process comprising the steps of:

a) providing an opioid receptor polypeptide comprising a second extracellular comprising the amino acid sequence GGTKVREDVDVIECSLQFPDDEYSWW, wherein the polypeptide is encoded for by a nucleic acid sequence comprising at least 30 contiguous bases of SEQ ID NO:1;

b) contacting said opioid receptor polypeptide with a composition comprising said substance;

c) detecting the ability of said substance to act as a specific agonist of said opioid receptor; and

d) isolating said substance if the ability of said substance to act as a specific agonist of the opioid receptor is detected.

109. (Amended three times) A process of isolating a substance with an ability to act as a specific agonist of a kappa opioid receptor, said process comprising the steps of:

a) providing an opioid receptor polypeptide comprising the second extracellular loop comprising the amino acid sequence GGTKVREDVDVIECCLQFPDDDYSWW and encoded for by a nucleic acid sequence comprising at least 60 contiguous bases of SEQ ID NO:11;

b) contacting said opioid receptor polypeptide with a composition comprising said substance;

c) detecting the ability of said substance to bind to said opioid receptor polypeptide; and

I2 cont

d) isolating said substance if the ability of said substance to specifically bind to the opioid receptor polypeptide is detected.

Sub 53 I3

117. (Amended twice) The process of claim 116, wherein the chimeric opioid receptor polypeptide comprises a second extracellular loop comprising the amino acid sequence GGTKVREDVDVIECSLQFPDDEYSWW.

Sub 54 I4

129. (Amended three times) A process of screening a substance for its ability to act as a specific agonist of a kappa opioid receptor comprising:

a) expressing a chimeric recombinant opioid receptor polypeptide comprising a second extracellular loop comprising the amino acid sequence GGTKVREDVDVIECSLQFPDDEYSWW, wherein said opioid receptor polypeptide is encoded by a nucleic acid sequence comprising at least 30 contiguous bases of SEQ ID NO:1;

b) contacting said substance with the opioid receptor polypeptide; and

c) detecting the ability of the substance to specifically bind to the opioid receptor polypeptide.

Sub 55 I5

137. (Amended) A process of screening a substance for its ability to act as a specific agonist of a kappa opioid receptor comprising:

a) expressing a chimeric recombinant opioid receptor polypeptide comprising the second extracellular loop comprising the amino acid sequence GGTKVREDVDVIECCLQFPDDDYSWW, wherein said chimeric opioid receptor polypeptide is encoded by a nucleic acid sequence comprising 60 contiguous bases of SEQ ID NO:11;